Ikarian Capital’s Q32 Bio QTTB Stock Holding History

Ikarian Capital’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,556	Closed	-$1.13M	–	335
2020 Q4	$1.13M	Buy	+5,556	New	+$1.07M	0.05%	173

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Ikarian Capital's QTTB Position: Q3 2024 in Review

Ikarian Capital sold out of Q32 Bio (QTTB) in Q3 2024, closing a stake of 109,094 shares — an estimated $1.96M sold.

Ikarian Capital first reported a position in QTTB in Q1 2024 and held it in 2 quarters. The position peaked at $1.96M in Q2 2024. 73 funds tracked by Wall St. Rank hold QTTB as of Q3 2024.

Ikarian Capital reported no remaining Q32 Bio position as of Q3 2024 after selling out during the quarter.
Ikarian Capital sold 109,094 Q32 Bio shares in Q3 2024, an estimated $1.96M.
Ikarian Capital first reported a position in Q32 Bio in Q1 2024 and held it in 2 quarters.
Ikarian Capital's Q32 Bio position peaked at $1.96M in Q2 2024.
73 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2024.

Based on Ikarian Capital's 13F filing for Q3 2024, filed 14 Nov 2024.